Analysts Issue Forecasts for OS Therapies Q1 Earnings

Key Points

• Brookline Capital Markets forecasts Q1 2026 EPS of ($0.19) and projects FY2026 EPS of ($0.67), with the company expected to turn slightly positive by FY2028 ($0.02) and improve to $0.32 EPS in FY2029.
• Analyst sentiment is cautiously positive: D. Boral Capital reiterated a Buy with a $20.00 price target, and the consensus rating is Moderate Buy with an average target of $18.50 (two Buys, one Hold).
• OS Therapies is an early-stage, loss-making biopharma trading around $1.73 with a market cap of about $68.4M, a negative PE, and reported ($0.41) EPS in the most recent quarter.

OS Therapies Incorporated (NYSEAMERICAN:OSTX - Free Report) - Equities researchers at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for shares of OS Therapies in a research note issued on Friday, May 1st. Brookline Capital Markets analyst K. Raja forecasts that the company will post earnings per share of ($0.19) for the quarter. The consensus estimate for OS Therapies' current full-year earnings is ($0.52) per share. Brookline Capital Markets also issued estimates for OS Therapies' Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.02 EPS and FY2029 earnings at $0.32 EPS.

Separately, D. Boral Capital reiterated a "buy" rating and issued a $20.00 price target on shares of OS Therapies in a report on Thursday, April 30th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $18.50.

OS Therapies Stock Performance

OSTX stock opened at $1.73 on Wednesday. The company's fifty day moving average price is $1.46 and its 200-day moving average price is $1.55. OS Therapies has a one year low of $1.15 and a one year high of $2.57. The company has a market capitalization of $68.39 million, a PE ratio of -1.75 and a beta of -1.34.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($0.41) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in OS Therapies in the second quarter worth about $63,000. Bridgeway Capital Management LLC bought a new stake in shares of OS Therapies in the 2nd quarter valued at approximately $47,000. Ground Swell Capital LLC bought a new stake in shares of OS Therapies in the 3rd quarter valued at approximately $40,000. CM Management LLC boosted its holdings in shares of OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company's stock worth $784,000 after purchasing an additional 25,000 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of OS Therapies during the 3rd quarter valued at approximately $169,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.